CP-675,206 In Patients With Advanced Melanoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

118 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-08-31

Study Completion Date

2009-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the efficacy, safety, and tolerability of monoclonal antibody therapy using 2 regimens for the treatment of advanced melanoma

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced Melanoma

NCT00585000

Melanoma

TERMINATED PHASE1

Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody

NCT00431275

Melanoma

COMPLETED PHASE1

CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy

NCT00257205

Melanoma

COMPLETED PHASE3

An Open-Label, Dose-Escalation Study of IMC-20D7S In Participants With Malignant Melanoma

NCT01137006

Malignant Melanoma

COMPLETED PHASE1

Treatment Use Study for Advanced Melanoma.

NCT00584493

Advanced Unresectable Melanoma

NO_LONGER_AVAILABLE

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Malignant Melanoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

10 mg/kg

pts treated at 10 mg/kg dose level on a monthly regimen

Group Type EXPERIMENTAL

CP-675,206

Intervention Type DRUG

pts treated at 10 mg/kg dose level on a monthly regimen

15 mg/kg

pts treated at 15 mg/kg dose level on a quarterly regimen

Group Type EXPERIMENTAL

CP-675,206

Intervention Type DRUG

pts treated at 15 mg/kg dose level on a quarterly regimen

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CP-675,206

pts treated at 10 mg/kg dose level on a monthly regimen

Intervention Type DRUG

CP-675,206

pts treated at 15 mg/kg dose level on a quarterly regimen

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically confirmed: Stage III (AJCC 6th edition)xxl unresectable melanoma, with measurable disease (either locally relapsed unresectable, in-transit lesions or unresectable draining nodes) or Stage IV melanoma, including:
* Metastasis to skin, subcutaneous tissues or distant lymph nodes, or
* Metastasis to lungs, or
* Metastasis to all other visceral sites with either LDH \<= ULN (upper limit of normal) or a single site of metastasis
* Note: Patients with melanoma of ocular origin will be considered ineligible
* Documented progressive disease following adjuvant therapy, localized therapy or other therapy for metastatic disease
* Measurable disease defined by at least one target lesion that can be accurately measured and whose size is at least 1.0 cm (by spiral CT) or 2.0 cm (by conventional techniques) in its longest diameter
* ECOG performance status of 0 or 1 Life expectancy of \> 3 months
* Either gender, aged 18 years and above
* Adequate bone marrow, hepatic, and renal functions determined within 2 weeks prior to starting therapy, defined as:
* Absolute neutrophil count \>= 1.5 x 10(9)cells/L
* Platelets \>= 100 x 10(9)/L
* Hemoglobin \>= 10 g/dL
* Aspartate and alanine aminotransferases (AST, ALT) \<= 2.5 x ULN (\<= 5 x ULN, if documented liver metastases are present)
* Total bilirubin \<= 1.5 x ULN
* Creatinine \<= 1.5 x ULN
* Patients must have recovered from all prior treatment related toxicities, to baseline status, or a CTC grade of 0 or 1. Post-surgical pain shall not be considered a basis for exclusion.
* Females must either be not of childbearing potential \[surgically sterilized, which includes tubal ligation, or at least 2 years postmenopausal; not breastfeeding\], or practicing 1 form of approved contraception for at least three months prior to entry into the study with 1 of the following methods: (a) oral contraceptives, (b) intrauterine device, (c) implanted contraceptive (such as Norplant®), (d) injected contraceptives (such as Depo-Provera®), (e) diaphragm, (f) sexual partner must use condom or be surgically sterilized, or (g) sexually inactive. Females of childbearing potential must be instructed to avoid pregnancy during study participation. Negative serum or urine pregnancy test must be documented during screening evaluation.
* Must be willing and able to provide written informed consent.

Exclusion Criteria

* Received immunotherapy for cancer within one month prior to the start of screening
* Patients previously treated on this protocol
* History of, or significant evidence of risk for, chronic inflammatory or autoimmune disease (e.g. Addison's disease, asthma, celiac disease, multiple sclerosis, Graves Disease, Hashimoto's thyroiditis, inflammatory bowel disease, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, etc.)
* Potential requirement for systemic corticosteroids or concurrent immunosuppressive drugs based on prior history.
* History of autoimmune colitis or other chronic gastrointestinal conditions associated with diarrhea or bleeding, or current acute colitis of any origin.
* Pregnant or lactating women.
* Dementia or significantly altered mental status that would prohibit the understanding or rendering of informed consent and compliance with the requirements of this protocol.
* Diagnosed or suspected brain metastases. Patients with past history of brain metastases but with no radiologic evidence within 12 weeks prior to enter into the protocol will be eligible.
* Any serious uncontrolled medical disorder or active infection, which would impair their ability to receive study treatment.
* Coexisting malignancies except for basal or squamous cell carcinoma of the skin.
* Received any prior CTLA4 inhibiting agent

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No